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Abstract
Background: Although the development of ileus is widespread and negatively im‐
pacts patient outcomes, the mechanism by which ileus develops remains unclear. The 
purpose of our study was to examine the contribution of myogenic mechanisms to 
postoperative ileus development and the involvement of inflammation in mediating 
intestinal smooth muscle dysfunction.
Methods: Contractile activity and the effects of CXCL1 were studied in a gut ma‐
nipulation model.
Key Results: Contraction amplitude in the ileum decreased significantly, while tone 
increased significantly in response to gut manipulation. Differences in contraction 
amplitude were affected by tetrodotoxin at earlier time points, but not at later time 
points.	 Agonist‐induced	 contractions	 in	 the	 small	 intestine	 decreased	 significantly	
with	 ileus	 development.	 Intestinal	 transit	 slowed	 significantly	 after	 the	 induction	
of ileus. Myosin light chain phosphorylation was significantly decreased and edema 
increased significantly in the intestinal wall. Conditioned media from mechanically 
activated macrophages depressed intestinal contractile activity. CXCL1 (GroA) was 
significantly increased in the mechanically activated macrophages and intestinal 
smooth muscle within 1 hour after induction of ileus compared with control cells 
and sham animals, respectively. Treatment with CXCL1 significantly decreased con‐
traction	amplitude	and	agonist‐induced	contractile	activity	and	increased	tone	in	the	
small	intestine.	In	the	gut	manipulation	model,	treatment	with	a	CXCR2	antagonist	
prevented	the	decrease	 in	agonist‐induced	contractile	activity	but	not	contraction	
amplitude.
Conclusions & Inferences: These data suggest that CXCL1, released from mac‐
rophages during intestinal wall stress, can suppress intestinal contractile activity. 
CXCL1 is a potential target for preventing or treating ileus in trauma patients.
K E Y W O R D S
CXCL1,	gastrointestinal	motility,	inflammation,	Intestine,	mechanotransduction
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1  | INTRODUC TION
Ileus,	or	depressed	intestinal	contractile	activity,	is	manifested	clini‐
cally as feeding intolerance, one of the most common postoperative 
complications. Grocott reported that 20% of orthopedic surgery pa‐
tients, 92% of general surgery patients, and 51% of urology surgery 
patients experienced gastrointestinal postoperative complications.1 
Virtually, all abdominal surgery patients experience some degree 
of	 ileus.	 In	general	surgery	patients,	gastrointestinal	complications	
were the leading reason for hospital readmission.2	 Ileus	 is	 also	 a	
common complication in trauma patients. Approximately 33% of 
moderate to severe trauma patients develop feeding intolerance, 
and 25% develop documented ileus.3	Ileus	significantly	increases	pa‐
tient care costs by necessitating the treatment of resultant compli‐
cations, feeding parenteral nutrition, and prolonging hospital stays.4 
More importantly, ileus causes significant patient discomfort and 
increases the risk of septic, pulmonary, and thromboembolic compli‐
cations, and malnutrition.5,6
Despite the widespread and negative impact of ileus on patient 
outcomes, the mechanism by which ileus develops remains unclear. 
Ileus	development	is	complex,	with	a	number	of	contributing	factors.	
Undoubtedly, opioid use contributes to ileus in surgical patients. 
However, in a trauma patient study, morphine equivalents were not 
significantly different between patients who developed feeding in‐
tolerance and those who did not,3 indicating that other factors con‐
tribute	to	slowed	gastrointestinal	motility.	Intestinal	edema	resulting	
from both excessive fluid use and/or inflammation also inhibits in‐
testinal contractile activity,7‐10 and in recent years, inflammation has 
been shown to contribute to ileus development.11‐15 A combination 
of factors, including inflammation, edema development, and opioid 
use, is likely to contribute to the development of ileus; however, the 
mechanisms by which these factors induce ileus may be different. 
The effects of inflammation, in particular, are poorly understood. 
Inflammation	affects	the	enteric	nervous	system	(ENS)	to	suppress	
intestinal motility; however, studies suggest that intestinal smooth 
muscle is also affected by inflammation.11,12	 In	 abdominal	 surgery	
patients, intestinal manipulation is thought to activate resident mac‐
rophages in the intestinal muscle layers resulting in cytokine and 
chemokine	release	and	recruitment	of	leukocytes.	Inflammation	re‐
sults in contractile dysfunction, not only in the manipulated sections 
of the bowel, but in most of the small and large intestine. Systemic 
inflammation in trauma and general surgery patients may also con‐
tribute to the development of ileus.
While the effects of intestinal edema on the ENS are unclear, we 
have shown that intestinal edema alone, in the absence of inflamma‐
tion, inhibits intestinal contractility by downregulating smooth mus‐
cle myosin light chain (MLC) phosphorylation.10 Edema development 
results in increased intestinal wall stress.16	Increased	stretch	of	in‐
testinal	smooth	muscle	cells	has	been	shown	to	down‐regulate	MLC	
phosphorylation.17	 Thus,	 edema‐induced	 mechanotransduction	
in the intestinal smooth muscle layers is one mechanism by which 
edema causes smooth muscle dysfunction. Little is known about 
the interaction between mechanotransduction and inflammatory 
mediator signaling in smooth muscle. Furthermore, the effects of 
increasing intestinal wall stress during edema development on mac‐
rophage activation are unclear.
While our investigations and others suggest that smooth mus‐
cle dysfunction contributes to the development of ileus, the drugs 
available to treat ileus target the ENS. We postulate that if intestinal 
smooth muscle is dysfunctional, drugs targeting the ENS will have 
limited effectiveness. Thus, the purpose of our study was to exam‐
ine the contribution of myogenic mechanisms to the development of 
postoperative ileus, and the involvement of inflammation in mediat‐
ing smooth muscle dysfunction.
2  | MATERIAL S AND METHODS
2.1 | Animal model
A gut manipulation (GM) model of postoperative ileus, described by 
Bauer,	was	utilized.18 Male Sprague Dawley rats weighing between 
250 and 350 g were used for all experiments. All procedures were 
approved by the University of Texas Medical School Care and Use 
Committee	 and	 are	 consistent	 with	 the	 NIH	 "Guide	 for	 the	 Care	
and	 Use	 of	 Laboratory	 Animals".	 Intestines	 were	 exteriorized	 via	
an	abdominal	 incision	in	anesthetized	rats.	The	small	 intestine	was	
gently compressed using a rolling motion between two sterile cot‐
ton applicators, in a proximal to distal direction. This procedure was 
repeated 3 times. After returning intestines to the abdominal cav‐
ity, the incision was closed. Sham animals underwent the same pro‐
cedure	with	a	laparotomy	but	no	exteriorization	or	manipulation	of	
the intestines. Naïve animals were not subjected to any procedures. 
Animals were sacrificed 0, 1, 2, 4, 12, and 24 hours after surgery, and 
the distal small intestine was collected for functional and biochemi‐
cal analyses.
In	a	separate	set	of	animals,	rats	were	treated	with	the	CXCR2	
antagonist,	SB265610	(3	mg/kg)	or	vehicle	(3%	DMSO)	via	intraper‐
itoneal injection, immediately after gut manipulation or sham sur‐
gery. Animals were sacrificed 24 hours after surgery, and intestinal 
segments were collected.
Key Points
•	 Spontaneous	 and	 agonist‐induced	 intestinal	 contractile	
activities and intestinal transit are decreased after gut 
manipulation.
• Macrophages release CXCL1 in response to mechanical 
stress.
• CXCL1 also increased in intestinal smooth muscle after 
gut manipulation in a rodent model and in the circulation 
of trauma patients who develop ileus.
•	 CXCL1	decreased	agonist‐induced	contractile	activity.
• These data suggest that CXCL1, released from mac‐
rophages during intestinal wall stress, can suppress intes‐
tinal contractile activity.
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2.2 | Intestinal contractile activity
Contractile activity was measured 0, 1, 2, 4, 12, and 24 hours after 
surgical manipulation in the distal small intestine, as described 
in previous publications.7,10,17 After equilibration, 10 minutes of 
basal contractile activity data was recorded. A subset of intestinal 
strips was treated with tetrodotoxin (TTX, 0.3 μmol/L added to the 
bath), and another 10 minutes of contractile activity was recorded. 
Agonist‐induced	 contractile	 activity	 was	 measured	 by	 adding	 in‐
creasing	concentrations	of	carbachol	to	the	organ	bath	in	5‐minute	
intervals. Total contractile activity was calculated as the area under 
the curve. Basal tone was defined as the average minimum of the 
contraction cycle. Amplitude was calculated as average cycle height. 
All	 force	 development	 was	 normalized	 to	 tissue	 cross‐sectional	
area. Measurements were performed on two separate intestinal 
strips and averaged.
For measurement of CXCL1 effects on contractile activity, in‐
testinal sections were equilibrated for 30 minutes. After recording 
5 minutes of baseline data, 200 ng/mL of CXCL1 (Biolegend, San 
Diego, CA) was added to the organ bath chamber and 10 minutes 
of	data	was	 recorded.	After	CXCL1	addition,	 a	 carbachol	dose‐re‐
sponse curve was generated as described above.
For determining the effects of conditioned media (see macro‐
phage conditions below), animals were subjected to sham surgery 
only	and	6	hours	later	tissue	was	collected	for	measurement	of	con‐
tractile activity. Equilibration and baseline measurements were as 
described above. Tissue was treated with media only, or media col‐
lected from macrophages after cyclical stretching. Media was added 
in	a	1:10	V:V	dilution.	Measurements	were	normalized	to	baseline.	
An aliquot of conditioned media was pretreated for 5 minutes with 
30 μmol/L oxyhemoglobin before adding to the organ bath chamber 
in a subset of experiments.
2.3 | Intestinal transit
At the time of gut manipulation, a silastic catheter for transit meas‐
urements was introduced into the proximal duodenum of mice. The 
catheter was then tunneled through the musculature of the left ab‐
dominal	wall	and	subcutaneous	tissue	and	externalized	behind	the	
neck.	At	the	time	of	sacrifice,	a	solution	of	70k‐dalton	nonabsorb‐
able	fluorescein	isothiocyanate	(FITC)	Dextran	(150	μL) was injected 
into the duodenum via the catheter and 45 minutes later, animals 
were sacrificed. The entire small intestine was carefully removed 
and divided into 10 equal segments. The end of each segment was 
clamped at the time of separation. Each segment was flushed with 
1	mL	of	 10%	mmol/L	 Tris‐buffer	 solution	 (TBS)	 into	 separate	 test	
tubes.8,9 Spectrophotometry (490 nmol/L) was used to determine 
FITC‐Dextran	concentrations	 in	each	sample	and	expressed	as	ab‐
sorbance units (AU). The geometric center was calculated based on 
a modified method published by Miller et al19 using the following 
equation:	geometric	center	=	∑	(fraction	of	FITC	per	segment	×	seg‐
ment number).
2.4 | Measurement of MLC phosphorylation by 
Western blotting
The mucosa was removed immediately after collection of intestines, 
and smooth muscle tissue lysates were generated and subjected to 
Western blotting as described previously.17 Antibodies used were 
MLC	 Ser19	 (Cell	 Signaling)	 and	 total	 MLC.	 ImageJ	 20,21 was used 
to	 quantify	 luminescence	 intensities.	 Glyceraldehyde‐3‐phosphate	
dehydrogenase (GAPDH) was used to control for protein loading 
amounts.
2.5 | Intestinal tissue water
Wet	to	dry	weight	ratios	were	measured	in	the	mid‐section	of	the	
small	 intestine.	 Intestinal	samples	were	weighed	 immediately	after	
collection.	 After	 drying	 in	 a	 65°C	 oven,	 samples	 were	 weighed	
again.	Wet	to	dry	weight	ratio	was	calculated	as	[(wet	weight)	−	(dry	
weight)]/dry weight.
2.6 | Cytokine array
Cytokine and chemokine levels in the rat ileal smooth muscle and 
conditioned medium were measured using a rat or human cytokine 
array	 (R&D	 Systems)	 following	 the	 manufacturer's	 directions.	 In	
the cytokine array kit, capture antibodies for the following 29 cy‐
tokines	 and	 chemokines	 are	 immobilized	 on	 nitrocellulose	 mem‐
brane:	 Cytokine‐induced	 neutrophil	 chemoattractant	 (CINC)‐1,	
CINC‐2α/β,	 CINC‐3,	 ciliary	 neurotrophic	 factor,	 fractalkine,	 granu‐
locyte	 macrophage	 colony‐stimulating	 factor,	 soluble	 intercellular	
adhesion	molecule	(sICAM)‐1,	interferon‐γ,	interleukin	(IL)‐1α,	IL‐1β, 
IL‐1	 receptor	 agonist,	 IL‐2,	 IL‐3,	 IL‐4,	 IL‐6,	 IL‐10,	 IL‐13,	 IL‐17,	 inter‐
feron	gamma–induced	protein‐10,	 lipopolysaccharide‐induced	CXC	
chemokine,	 L‐selectin,	 monokine	 induced	 by	 interferon	 gamma,	
macrophage	 inflammatory	protein,	MIP‐3α, regulated upon activa‐
tion	 normal	 T‐cell	 expressed,	 thymus	 chemokine,	 tissue	 inhibitor	
of	metalloproteinase‐1,	tumor	necrosis	factor	(TNF)α, and vascular 
endothelial growth factor. Antibody binding was quantified using 
ImageJ.20,21	CXCL1	levels	were	confirmed	by	ELISA.
2.7 | Human primary cell isolation and culture
Disease‐free	small	intestinal	tissue	was	collected	from	organ	donor	
patients with the generous consent of a family member and ap‐
proval by the Committee for the Protection of Human Subjects at 
the University of Texas Health Science Center at Houston. Human 
intestinal	smooth	muscle	cells	(hISMC)	were	isolated	and	character‐
ized	as	previously	described.17
2.8 | Cell stretching
THP‐1	or	hISMC	were	seeded	onto	6‐well	BioFlex® culture plates with 
flexible silicone elastomer bottoms (Flexcell) coated with 1 mg/mL 
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poly‐D‐lysine	 (Sigma).	 The	 FX‐4000™	Tension	 System	 (Flexcell)	was	
used to apply mechanical force to cells. The control cyclical stretch 
(CCS) and edema cyclical stretch (ECS) protocols were designed based 
on the spontaneous contraction amplitude and frequency measured in 
vivo in previous experiments.16,17	For	THP‐1	cells,	media	was	collected	
and used for subsequent cell and contractile activity experiments.
2.9 | Treatment of hISMC with conditioned 
THP‐1 media
THP‐1	 cells	 are	 an	 immortalized	 human	 monocyte‐like	 cell	 line.	
THP‐1	cells	 (ATCC)	were	 seeded	onto	Flexcell	plates	and	1	hour	
later	 activated	 with	 phorbol‐12‐myristate‐13‐acetate	 (PMA,	
12.5	ng/mL).	Twenty‐four	hours	after	PMA	treatment,	cells	were	
subjected to either CCS or ECS protocols. Media, termed “condi‐
tioned media,” was collected immediately after the 4 hours stretch 
protocol. Conditioned media was either used to treat intestinal 
strips,	as	described	above,	or	added	to	hISMC,	which	were	previ‐
ously seeded onto Flexcell plates. Two hours after pretreatment 
with	conditioned	media,	hISMC	were	subjected	to	either	the	CCS	
or ECS for 4 hours
2.10 | Patient blood sample collection
Blood samples were obtained from severely injured trauma patients 
48 to 72 hours following their admission to the intensive care unit 
as part of an ongoing prospective study with prior approval obtained 
from	 the	 University	 of	 Texas	 Health	 Science	 Center	 Institutional	
Review	Board	(HSC‐GEN‐11‐0213).	We	obtained	consent	from	the	
patient	or	their	legally	authorized	representative.	Samples	were	cen‐
trifuged	within	1	hour	of	collection,	and	plasma	was	stored	at	−80	
degrees until assayed.
F I G U R E  1   Contractile activity after gut manipulation. Contractile activity was measured in the ileum after gut manipulation to induce 
ileus	or	sham	operation	(laparotomy	only).	Intestinal	sections	were	treated	with	tetrodotoxin	(0.3	μmol/L) or vehicle. A, Contraction 
amplitude	measured	up	to	24	h	after	surgery.	B,	Tone	(average	cycle	minimum)	measured	up	to	24	h	after	surgery.	C,	Carbachol	dose‐
response	curve	to	measure	agonist‐induced	contractile	activity	12	h	after	surgery.	D,	Agonist‐induced	contractile	activity	(10−6 M carbachol) 
measured 12 h after induction of ileus or sham surgery in the presence or absence of tetrodotoxin (0.3 μmol/L). E, Relaxation measured 4 h 
after	induction	of	ileus	or	sham	surgery.	(Panels	A‐E:	n	=	6‐10	per	group;	*,	P	<	.05	vs	Sham;	ł,	P < .05 vs TTX) F, Geometric Center, a measure 
of	intestinal	transit,	measured	12	h	after	induction	of	ileus	or	sham	surgery.	(n	=	4	per	group;	*,	P < .05 vs Sham)
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2.11 | Statistics
Analysis	 of	 Variance	 (ANOVA)	 and	 t tests were used to compare 
groups where appropriate. A P value <.05 was considered significant. 
When	ANOVA	was	significant,	Fishers	LSD	was	used	for	post	hoc	
analysis. Data are shown as the mean ± standard error of the mean.
3  | RESULTS
3.1 | Contractile dysfunction
Figure 1 shows the intestinal contractile activity measured 1 to 
24	 hours	 after	 gut	 manipulation.	 One	 hour	 after	 surgery,	 contrac‐
tion amplitude decreased significantly in the GM group compared 
with the SHAM group (0.078 ± 0.020 vs 0.023 ± 0.002, Sham vs GM; 
P = .038); however, treatment with tetrodotoxin ameliorated the dif‐
ference (0.057 ± 0.008 vs 0.043 ± 0.004, Sham vs GM; P = .14), as 
shown in Figure 1A. There were no differences in contraction am‐
plitude 2 hours after surgery. Four hours after surgery, contraction 
amplitude decreased significantly in the GM group compared with the 
SHAM	group	(0.051	±	0.008	vs	0.026	±	0.004,	Sham	vs	GM;	P = .013) 
and treatment with tetrodotoxin ameliorated the difference, similar 
to 1 hour after surgery (0.052 ± 0.007 vs 0.039 ± 0.004, Sham vs GM; 
P = .12). At 1 and 4 hours after surgery, tetrodotoxin induced a signifi‐
cant increase in contraction amplitude, but had no significant effects 
at other time points. At 12 and 24 hours after surgery, contraction am‐
plitude was significantly decreased in the GM group compared with 
the SHAM group (12 hours: 0.130 ± 0.019 vs 0.037 ± 0.005, P = .0003; 
24	hours:	0.064	±	0.010	vs	0.029	±	0.004,	P	=	.006;	sham	vs	GM).	In	
contrast to the earlier time points, tetrodotoxin did not ameliorate the 
differences in contraction amplitude at 12 and 24 hours after surgery. 
Contraction amplitude was significantly lower in the GM group com‐
pared with the Sham group after tetrodotoxin treatment (12 hours: 
0.103	±	0.014	vs	0.036	±	0.008,	P	=	.001;	24	hours:	0.053	±	0.006	vs	
0.022 ± 0.003, P = .0004; sham vs GM).
Figure 1B shows changes in intestinal tone after gut manipulation 
compared with sham surgery. From 1 to 4 hours after surgery, tone in‐
creased significantly in the GM group compared with the Sham group, 
even when tissue was pretreated with tetrodotoxin (Vehicle: P	=	.026,	
0.00009, 0.001, at 1, 2, and 4 hours; tetrodotoxin: P	=	 .009,	0.016,	
0.014, at 1, 2, and 4 hours). At 12 hours after surgery, there were no 
differences in intestinal tone in the GM group compared with Sham 
either with or without tetrodotoxin (P = .48 and 0.45, respectively). At 
24 hours after surgery, the tone was, again, significantly higher in the 
GM group compared with the Sham group, but only after tetrodotoxin 
treatment (0.32 ± 0.04 vs 0.41 ± 0.03, Sham vs GM, VEH, P = .13; 
0.18 ± 0.03 vs 0.28 ± 0.03, Sham vs GM, TTX, P	=	.016).	Tetrodotoxin	
significantly	decreased	tone	in	the	GM	group	from	4‐24	hours	after	
surgery, and at the 24 hours time point in the Sham group.
The	carbachol	dose‐response	curve	at	12	hours	after	surgery	is	
shown	in	Figure	1C.	Agonist‐induced	contractile	activity	was	signifi‐
cantly reduced in the GM group compared with the SHAM group, 
from 10−8 M to 10−6 M carbachol concentrations (P = .05, 0.007, and 
2	×	10−5 for 10−8, 10−7, and 10−6	M	carbachol).	The	carbachol	dose‐
response	curve	24	hours	after	surgery	looked	similar	to	the	12‐hour	
curve	 (data	 not	 shown).	 Carbachol‐induced	 contractions	were	 not	
different at the 1, 2 and 4 hours time points (data not shown). The 
effects of tetrodotoxin were measured at the highest carbachol dose 
(10−6 M) 12 hours after surgery, as shown in Figure 1D. Tetrodotoxin 
reduced	 agonist‐induced	 contractile	 activity	 in	 the	 Sham	 group;	
however,	 agonist‐induced	 contractile	 activity	 was	 significantly	
reduced in the GM group compared with the Sham group with or 
without tetrodotoxin (P	 =	 2	 ×	 10−5 and 0.02 for GM vs SHAM in 
VEH and TTX treated groups; P	 =	 9	 ×	 10−4, SHAM TTX vs VEH). 
Relaxation	after	agonist‐induced	contraction	was	measured	4	hours	
after induction of ileus (at the point of maximal differences in tone). 
Relaxation was significantly suppressed in the GM group compared 
with the Sham group, as shown in Figure 1E.
Intestinal	transit,	measured	in	a	subset	of	animals	12	hours	after	
surgery, is shown in Figure 1F. The geometric center was signifi‐
cantly decreased in the GM group compared with the Sham group 
(5.57	±	0.57	vs	3.24	±	0.68,	P = .039).
3.2 | Changes in MLC phosphorylation and edema
MLC	phosphorylation,	the	rate‐limiting	step	for	smooth	muscle	con‐
traction, was measured in intestinal smooth muscle. Representative 
blots and the ratio of MLC phosphorylation are shown in 
Figure 2A,B. Phosphorylated serine 19 was significantly decreased 
in the GM group 24 hours after surgery compared with the Sham 
group (0.95 ± 0.08 vs 0.52 ± 0.07, Sham vs GM, P	=	.0006).
Wet to dry weight ratios, indicating the development of intersti‐
tial intestinal wall edema, increased significantly from 4 to 24 hours 
after surgery in the GM group compared with the Sham group 
(Figure	2C).	 In	addition,	wet	 to	dry	weight	 ratios	 increased	signifi‐
cantly from 4 to 24 hours after surgery in the GM group compared 
with the 0 time point.
3.3 | Effects of conditioned media from 
macrophages on contractile activity
We determined the effects of mechanical stimulation of mac‐
rophages on contractile activity and cytokine production. We col‐
lected “conditioned media” from macrophages subjected to CCS or 
ECS, mimicking intestinal wall mechanical stimuli under normal or 
edematous conditions, respectively. As shown in Figure 3A, condi‐
tioned media had no significant effects on contractile activity of in‐
testinal	sections	collected	from	naïve	rats.	In	contrast,	conditioned	
media collected from macrophages subjected to ECS, but not CCS, 
inhibited the intestinal contractile activity in Sham animals (sub‐
jected to laparotomy only) (Figure 3B). The effects of conditioned 
media collected from macrophages subjected to CCS showed no dif‐
ferences	compared	with	media	alone.	Intestinal	contractile	activity	
was still inhibited by ECS conditioned media, after oxyhemoglobin 
treatment	to	oxidize	nitric	oxide,	suggesting	that	nitric	oxide	was	not	
causing the inhibition of contractile activity (Figure 3B).
6 of 12  |     DOCSA et Al.
Primary	hISMC	were	treated	with	conditioned	media	from	mac‐
rophages	subjected	to	either	CCS	or	ECS	(Figure	3C).	When	hISMC	
were subjected to CCS, the conditioned media did not affect MLC 
phosphorylation.	When	primary	hISMC	were	subjected	to	ECS,	con‐
ditioned media from macrophages subjected to ECS significantly 
inhibited MLC phosphorylation compared with conditioned media 
from macrophages subjected to CCS.
Conditioned media from macrophages subjected to CCS or ECS 
were	analyzed	for	cytokine	content.	In	Figure	3D,3,	cytokine	levels	
in media are shown relative to quiescent cells. There are relatively 
small	changes	in	the	media	of	macrophages	subjected	to	CCS.	In	con‐
trast, several cytokines increase significantly in the media from mac‐
rophages subjected to ECS, including CXCL1, which was increased 
almost	3‐fold.
3.4 | Cytokine production in vivo
To determine if in vivo changes in cytokines were similar to 
changes in macrophages subjected to mechanical stress in vitro, 
we collected intestinal tissue after gut manipulation or sham sur‐
gery and measured cytokine levels in the smooth muscle layers. 
Data are shown as a ratio of GM to SHAM. As shown in Figure 4A, 
CXCL1	 was	 increased	 8‐fold	 within	 1	 hour	 after	 gut	 manipula‐
tion. The increased CXCL1 levels were sustained until at least 
24	hours	after	gut	manipulation.	LIX	(CXCL5)	was	also	upregulated	
in smooth muscle tissue after gut manipulation in an early and sus‐
tained	manner.	At	later	time	points,	IL‐1β and TNFα were upregu‐
lated at 4 and 12 hours, respectively.
The	upregulation	of	CXCL1	was	confirmed	by	ELISA.	As	shown	
in Figure 4B, CXCL1 was significantly increased within 1 hours 
after GM compared with the Sham group. We also determined 
circulating CXCL1 levels in severely injured trauma patients 
48‐72	hours	after	hospital	admittance.	Plasma	CXCL1	levels	were	
significantly upregulated in trauma patients who developed ileus 
compared to trauma patients who did not develop ileus (P = .004) 
(Figure 4C).
3.5 | Effects of CXCL1 on contractile activity
The effects of CXCL1 (200 ng/mL) on intestinal contractile activ‐
ity were measured in an organ bath in animals subjected to sham 
surgery only (Figure 5A). CXCL1 induced a significant decrease in 
contraction amplitude and a significant increase in tone, compared 
with	VEH	treatment	(0.1%	bovine	serum	albumin	in	phosphate‐buff‐
ered	 saline).	 Agonist‐induced	 contractile	 activity	 was	 significantly	
decreased after treatment with CXCL1 (Figure 5B).
To further explore the effects of CXCL1 on contractile activ‐
ity, we measured contractile activity after either sham surgery 
or gut manipulation in animals treated with a CXCR2 antago‐
nist	 (SB265610,	 3	 mg/mL)	 or	 vehicle	 (3%	 DMSO).	 As	 shown	 in	
Figure 5C, treatment with the CXCR2 antagonist did not amelio‐
rate the decreased contraction amplitude induced by gut manip‐
ulation.	In	contrast,	inhibition	of	CXCR2	abrogated	the	decreased	
agonist‐induced	contractile	activity	 induced	by	gut	manipulation	
(Figure 5D).
4  | DISCUSSION
Our	data	suggest	that	gut	manipulation‐induced	ileus	is	mediated,	at	
least	in	part,	by	intestinal	macrophage	secretion	of	CXCL1.	In	sup‐
port of these observations are the early and sustained increases in 
CXCL1 in intestinal smooth muscle, a loss of function experiment 
F I G U R E  2   Myosin light chain (MLC) phosphorylation and the 
development	of	intestinal	edema.	A,	A	sample	blot	of	phospho‐
MLC,	MLC,	and	GAPDH	in	sham‐operated	animals	(S)	and	after	
gut manipulation (GM) to induce ileus, measured in intestinal 
smooth muscle layers of the ileum 24 h after surgery. B, The ratio 
of	phospho‐MLC	to	MLC	24	h	after	sham	operation	(SHAM)	or	gut	
manipulation	(GM)	to	induce	ileus.	(n	=	11	per	group;	**,	P < .001) 
C, Edema development, indicated by wet to dry weight ratios, was 
measured at 0, 1, 2, 4, 12, and 24 h after surgery to induce ileus 
(GM) or sham surgery (SHAM). (n = 31 for 0 h, 10 for 1 h groups, 10 
for	2	h	groups,	11	for	4	h	groups,	6	for	12	h	groups,	and	25	and	16,	
respectively,	for	Sham	and	GM	groups	at	24	h;	*,	P < .05 vs sham at 
same	time	point;	ł,	P < .0005 vs 0 h time point)
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with CXCL1, and the attenuation of intestinal contractile dysfunc‐
tion	when	CXCL	effects	were	antagonized.	Finally,	trauma	patients	
with ileus showed a similar increase in CXCL1 as our experimental 
model.
According to the Centers for Disease Control and Prevention, 
2.8	 million	 people	 were	 hospitalized	 for	 traumatic	 injuries	 in	
2015.22 Feeding intolerance affects more than 30% of moderate to 
severe trauma patients, and 25% of those patients are diagnosed 
with ileus.3 Considering the large number of trauma patients re‐
ported by the CDC, feeding intolerance and ileus affect a very 
large number of people. The terms ileus and feeding intolerance 
are interrelated, with the main difference being the clinical diag‐
nosis.	In	addition,	ileus	refers	specifically	to	suppressed	motility	in	
the intestines, while feeding intolerance can be attributed to other 
F I G U R E  3  Effects	of	conditioned	media	from	macrophages	(activated	THP‐1	cells)	on	contractile	activity	and	myosin	light	chain	(MLC)	
phosphorylation.	Intestinal	sections	were	treated	with	“conditioned	media”	collected	from	macrophages	subjected	to	control	cyclical	stretch	
(CCS) or edema cyclical stretch (ECS) conditions, mimicking intestinal wall mechanical stimuli under normal conditions or when the intestinal 
wall becomes edematous, respectively. A, Effects of conditioned media on contractile activity in intestinal sections collected from naïve 
(untreated,	0	h)	animals.	(n	=	15‐16	per	group).	B,	Effects	of	conditioned	media	on	contractile	activity	in	intestinal	sections	collected	24	h	
after	laparotomy	only.	In	the	ECS	+	Oxyhemoglobin	group,	the	media	was	pretreated	with	oxyhemoglobin	(30	μmol/L) for 5 min before use. 
(n	=	12	per	group	for	media,	CCS,	and	ECS	groups;	n	=	8	for	the	ECS	+	OxyHb	group;	*,	P < .05). C, Effects of conditioned media on MLC 
phosphorylation	in	primary	human	intestinal	smooth	muscle	cells.	(n	=	6	per	group,	*,	P	<	.05)	D‐E,	Cytokine	profile	in	conditioned	media	
after 4 h of CCS (D) or ECS (E). Data are shown as a ratio of stretched cells to control quiescent (Q) cells. The solid line indicated no change; 
below	the	line	indicates	decreases	in	response	to	the	stretching	protocol	and	above	the	line	indicates	increases.	(n	=	3	per	group,	*,	P < .05 vs 
CCS)	(Media	=	Media	alone,	CCS	=	media	collected	from	THP‐1	subjected	to	controlled	cyclical	stretch,	ECS	=	media	collected	from	THP‐1	
subjected to edema cyclical stretch program)
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parts of the gastrointestinal tract. The salient point is that both 
ileus, and feeding intolerance are caused by depressed gastroin‐
testinal motility. Unfortunately, there is a paucity of drugs to treat 
depressed gastrointestinal motility, and the available drugs have 
limited or no effectiveness in trauma patients.23 Understanding 
the mechanism(s) by which gastrointestinal motility disorders 
develop in trauma patients is important in addressing the need 
for new and effective drugs to treat depressed gastrointestinal 
motility	in	trauma	patients.	Our	results	elucidate	the	mechanisms	
by which ileus develops in trauma patients.
Many of the drugs to improve postsurgical gastrointestinal mo‐
tility target the central or ENS and some are principally designed 
to	counter	the	effects	of	opioid‐induced	 ileus.	We	show	that	both	
spontaneous contractile activity (contraction amplitude) and ago‐
nist‐induced	 (carbachol‐induced)	contractile	activity	are	decreased	
from	12‐24	hours	after	surgery,	even	in	the	presence	of	tetrodotoxin	
F I G U R E  4   Cytokine profile in intestinal smooth muscle after induction of ileus and in human plasma after trauma. A, The cytokine profile 
is shown as a ratio of gut manipulation (GM) to sham surgery measured at the indicated time points. The solid line indicates no change; 
below the line indicates decreases in the GM group compared with the Sham group and above the line indicates increases. (n = 3 per group). 
B,	CXCL‐1	measured	by	ELISA	in	rat	intestinal	smooth	muscle	collected	at	0,	1,	2,	4,	12,	and	24	h	after	gut	manipulation	to	induce	ileus	or	
sham	surgery.	(n	=	3‐4	per	group;	**,	P	<	.01;	*,	P	<	.05).	C,	CXCL‐1	levels	in	the	plasma	of	human	trauma	patients	measured	between	48‐72	h	
after hospital admittance. Trauma patients in the “no ileus” group had no symptoms of slowed gastrointestinal motility, whereas patients in 
the	“ileus”	group	had	documented	ileus.	(n	=	15	and	13	for	the	no	ileus	and	ileus	groups,	respectively;	**,	P < .01)
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(Figure 1 A and D). Furthermore, MLC phosphorylation is decreased, 
as shown in Figure 2. These data support the hypothesis that smooth 
muscle dysfunction contributes to ileus, and, therefore, drugs tar‐
geting the ENS or CNS will be ineffective in improving gastrointesti‐
nal motility in trauma patients.
The smooth muscle dysfunction observed in our study agrees 
with Farro et al, in which impaired smooth muscle contractility 
after gut manipulation was also observed.24 However, the time 
course of changes in smooth muscle function in our experiments 
was somewhat different from the Farro study. The suppressed 
smooth	muscle	dysfunction	from	12‐24	hours	after	gut	manipula‐
tion in the Farro study was similar to our study. However, at earlier 
time	points	 (1‐4	 hours)	 the	 differences	 in	 contraction	 amplitude	
measured in our study were tetrodotoxin sensitive, indicating 
that the differences in contractile activity were due to changes in 
the ENS; whereas, in the Farro study smooth muscle dysfunction 
was	 observed	 1.5	 hours	 after	 gut	 manipulation.	 In	 addition,	 we	
observed	no	 significant	 changes	 in	 agonist‐induced	 contractions	
until 12 hours after surgery, while Farro measured reduced ago‐
nist‐induced	contractions	as	early	as	1.5	hours	after	surgery.	The	
differences in the time course may reflect differences in the ani‐
mal	species.	Our	study	was	conducted	in	rats,	whereas	the	Farro	
study was conducted in mice. Despite the differences, both stud‐
ies are in agreement as to the smooth muscle dysfunction and the 
biphasic nature of the contractile dysfunction.
While changes in contraction amplitude are likely to result in 
changes in intestinal transit, as demonstrated in Figure 1E, changes 
in tone are more difficult to interpret. Tone was calculated as the av‐
erage minimum of the contraction cycle. All intestinal segments were 
adjusted to an average 0.5 g load when mounted in the organ bath 
chamber, allowed to warm for 10 minutes, then readjusted to the 
0.5 g load. The intestinal segments were then allowed to relax with 
no	more	adjustments.	 In	our	experience,	 the	tone	and	contraction	
amplitude change very little after the 30 minute equilibration period, 
F I G U R E  5   Intestinal	contractile	activity	in	response	to	CXCL1	and	a	CXCR2	antagonist.	A,	Changes	in	intestinal	contractile	activity,	
including both amplitude and tone, in response to CXCL1 treatment (200 ng/mL) or vehicle treatment (VEH, 0.1% BSA) of the intestinal 
segment	(ex	vivo).	(n	=	8	per	group;	*,	P	<	.05	vs	VEH	treatment).	B,	Changes	in	agonist‐induced	intestinal	contractile	activity	in	response	
to	CXCL1	treatment	(200	ng/mL)	or	vehicle	treatment	(0.1%	BSA)	(n	=	8	per	group;	*,	P < .05 vs VEH treatment). C, Changes in intestinal 
contraction	amplitude	in	response	to	CXCR2	antagonist	treatment	(SB265610,	3	mg/kg,	IP)	or	vehicle	(3%	DMSO)	immediately	after	sham	
surgery	(SHAM)	or	induction	of	ileus	by	gut	manipulation	(GM).	(n	=	7	per	group;	*,	P	<	.05	vs	SHAM).	D,	Changes	in	intestinal	agonist‐
induced	contractile	activity	in	response	to	CXCR2	antagonist	treatment	(SB265610,	3	mg/kg,	IP)	or	vehicle	(3%	DMSO)	immediately	after	
sham	surgery	(SHAM)	or	induction	of	ileus	by	gut	manipulation	(GM).	(n	=	7	per	group;	*,	P < .05 vs SHAM)
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in the absence of any treatments. We observed a higher tone in the 
gut manipulation group compared with the sham group. This signifi‐
cantly altered tone was preserved after tetrodotoxin treatment, in‐
dicating that the changes in tone were myogenic, not neurogenic. 
In	 fact,	 at	 24	 hours	 after	 surgery,	 tone	 was	 significantly	 reduced	
in both the SHAM and GM groups in the presence of tetrodotoxin 
(Figure 1B), indicating that the ENS had a positive effect on tone, and 
the differences in tone due to myogenic effects were unmasked with 
TTX treatment. Farro et al demonstrate impaired relaxation of intes‐
tinal smooth muscle after induction of ileus.24 The increased tone in 
our study may be due to impaired relaxation. Figure 1E shows that 
relaxation	after	agonist‐induced	contractions	 is	 indeed	suppressed	
in the ileus group compared with the Sham group, supporting the 
idea that the ability of smooth muscle to both contract and relax is 
impaired.
Ileus	in	trauma	patients	or	postoperative	patients	is	thought	to	
be induced, in part, by inflammatory injury to the smooth muscle lay‐
ers. Kalff demonstrated that leukocytes infiltrate into the rat intes‐
tinal muscularis during the development of ileus.12,18 Farro showed 
increased mRNA levels for a number of different inflammatory me‐
diators in intestinal smooth muscle, including TNFα,	Il1α,	IL1β,	IL6,	
and CXCL1.24 We also observed increased inflammation in intestinal 
smooth	muscle	after	induction	of	ileus.	In	addition	to	increased	cy‐
tokine production, intestinal edema developed within 4 hours after 
surgery (Figure 2C). Edema development in the absence of vascular 
changes or hemodilution is indicative of inflammation.
We have shown previously that edema itself, in the absence of 
gut manipulation, can decrease intestinal contractile activity.7,10 Cox 
et al have shown that edema also results in increased mechanical 
stress in the intestinal wall.16 This increased stress decreases MLC 
phosphorylation in primary intestinal smooth muscle cells.17 We 
speculated that increased mechanical stress may also affect the res‐
ident macrophages in the intestinal wall. Thus, we subjected acti‐
vated macrophages to either control cyclical stretch (CCS), as the 
macrophages would experience under physiological conditions, or 
edema cyclical stretch (ECS), which intestinal macrophages would 
experience after edema development. We collected the “condi‐
tioned”	media	after	stretching	the	macrophages.	Interestingly,	con‐
ditioned media from macrophages subjected to CCS or ECS did not 
affect intestinal contractile activity of intestinal strips collected from 
naïve	animals.	In	contrast,	conditioned	media	collected	from	macro‐
phages subjected to ECS significantly decreased contractile activity 
of tissue sections after surgical stress (Figure 3). Pretreatment of the 
conditioned media with oxyhemoglobin had no effect; thus, the in‐
hibitory effect of the conditioned media on contractile activity was 
not due to nitric oxide release from the macrophages. Furthermore, 
treatment	 of	 primary	 hISMC	 with	 conditioned	 media	 had	 similar	
results; conditioned media from macrophages subjected to ECS 
inhibited	MLC	phosphorylation	 in	 ISMC	subjected	to	ECS,	but	not	
CCS. We conclude from these data, that when macrophages are sub‐
jected to mechanical stress, such as they would experience during 
intestinal edema development or gut manipulation, the macrophage 
secretome inhibits intestinal contractile activity. Furthermore, the 
macrophage secretome did not affect naive tissue, but only affected 
tissue already subjected to stress.
To identify the substance secreted from macrophages that in‐
hibited intestinal contractile activity, we used a cytokine array to 
determine changes in a panel of cytokines in the conditioned media. 
In	macrophages	subjected	to	CCS,	there	were	no	significant	changes	
in	cytokines	compared	with	quiescent	cells.	In	media	collected	after	
macrophages were subjected to ECS, CXCL1 (GroA) was upregu‐
lated (Figure 3D,3). CXCL1 was also the predominant cytokine up‐
regulated in vivo in intestinal smooth muscle after gut manipulation 
(Figure 4A). CXCL1 was upregulated within 1 hours after gut ma‐
nipulation, and the upregulation was sustained for up to 24 hours 
(Figure	4F).	Of	note,	CXCL1	was	also	upregulated	in	trauma	patients	
who developed ileus versus trauma patients who did not develop 
ileus (Figure 4G). CXCL1 was upregulated very early after gut manip‐
ulation and was likely increased before leukocyte infiltration. Thus, 
CXCL1 was likely secreted by resident macrophages in the intestinal 
smooth muscle layers. The early release of CXCL1 is in agreement 
with the study by Farro, in which CXCL1 was significantly increased 
within the first 1.5 hours after gut manipulation.24 However, unlike 
the Farro study, we did not see early increases in TNFα,	 IL‐1β, or 
IL‐1α.	In	our	study,	IL‐1β increased 4 hours after gut manipulation and 
TNFα increased 12 hours after gut manipulation. These differences 
could have arisen for a number of different reasons. Firstly, Farro 
was measuring mRNA levels and we measure actual cytokine levels. 
Secondly, we measured the ratio of cytokines in GM to Sham. Thus, 
IL‐1β and TNFα could have increased in both groups due to surgical 
stress.	In	the	Farro	manuscript,	the	cytokines	are	shown	in	the	gut	
manipulation group only; the cytokine levels in the laparotomy only 
group are not shown.
According to Figure 4, CXCL1 was the first cytokine to increase 
after gut manipulation, and CXCL1 was, for the most part, the most 
increased cytokine. Thus, we investigated the effects of CXCL1 
on intestinal contractile activity (Figure 5). When intestinal tissues 
from sham animals (laparotomy only) were treated with CXCL1, con‐
traction amplitude decreased slightly but significantly and tone in‐
creased significantly compared with vehicle treatment (Figure 5A). 
CXCL1	substantially	decreased	agonist‐induced	contractile	activity	
(Figure 5B). These effects of CXCL1 on intestinal contractile activity 
are similar to the effects of gut manipulation on intestinal contractile 
activity.	 If	animals	were	treated	with	a	CXCR2	antagonist	 immedi‐
ately after gut manipulation, spontaneous contractile activity was 
unaffected	 (Figure	5C).	 In	 contrast,	CXCR2	antagonism	prevented	
decreases	 in	agonist‐induced	contractile	activity	after	gut	manipu‐
lation	 (Figure	 5D).	One	 drawback	 of	 the	 study	 is	 that	 the	CXCR2	
antagonist has off target effects which may affect intestinal con‐
tractile activity.
CXCL1	is	a	member	of	the	C‐X‐C	chemokine	family.	CXCL1	is	
upregulated in many inflammatory processes, often in response to 
nuclear factor Kβ	 (NF‐kβ)	 or	 CCAAT‐enhancer‐binding	 proteinsβ 
(C/EBPβ). The mechanism by which CXCL1 is increased in intes‐
tinal smooth muscle is unclear. However, CXCL1 was increased 
in the conditioned media of cyclically stretched macrophages 
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subjected to increased stretch (Figure 3E). These data suggest 
that CXCL1 is secreted by macrophages (or other cells types in the 
intestinal smooth muscle) in response to mechanical stimuli. We 
have	shown	previously	that	NF‐kβ which can upregulate CXCL1, is 
increased in edematous intestinal smooth muscle (ie tissue that is 
experiencing increased mechanical stretch) resulting in decreased 
intestinal motility.25,26	Thus,	NF‐kB	may	upregulate	CXCL1	in	re‐
sponse to increased stretch.
The mechanism by which CXCL1 can affect smooth muscle 
contractility is unclear. CXCL1 acts as a full agonist at the CXCR2 
receptor. CXCR2 activation triggers a number of downstream 
pathways, including Akt signaling and PAK1 signaling.27,28 We 
have shown previously that increased PAK1 activation can inhibit 
intestinal contractile activity via decreased MYPT1 phosphoryla‐
tion.17 Thus, CXCL1 may signal through PAK1 to decrease intesti‐
nal	smooth	muscle	contractility.	Interestingly,	in	vascular	smooth	
muscle, Akt signaling was shown to increase smooth muscle tone 
in a manner that was uncoupled to MLC phosphorylation.29,30 This 
may explain the disparate results concerning decreased contrac‐
tion amplitude versus increased tone (Figure 1).
In	 summary,	 both	 spontaneous	 and	 agonist‐induced	 intestinal	
contractile activities were decreased after gut manipulation. The de‐
creased contractile activity resulted in decreased intestinal transit. 
Resident macrophages are a likely source of cytokine release early 
in the development of contractile dysfunction. Thus, we subjected 
macrophages to mechanical stress and showed that CXCL1 was re‐
leased. CXCL1 also increased in intestinal smooth muscle after gut 
manipulation in a rodent model and in the circulation of trauma pa‐
tients	who	develop	ileus.	CXCL1	decreased	agonist‐induced	contrac‐
tile	activity;	the	suppression	of	agonist‐induced	contractile	activity	
could be blocked with a CXCR2 antagonist. Taken together, these 
data suggest that CXCL1, released from macrophages during intesti‐
nal wall stress, can suppress intestinal contractile activity. CXCL1 is a 
potential target for treating decreased contractile activity in trauma 
and surgical patients.
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